



Cairo University

ALZHEIMER'S DISEASE PROGRESSION ANALYSIS AND CLASSIFICATION USING T₁-WEIGHTED MRI

By

Basma Hassan Ahmed Ali

A Thesis Submitted to the
Faculty of Engineering at Cairo University
in Partial Fulfillment of the
Requirements for the Degree of
MASTER OF SCIENCE
in
Biomedical Engineering and Systems

FACULTY OF ENGINEERING, CAIRO UNIVERSITY
GIZA, EGYPT
2019

ALZHEIMER'S DISEASE PROGRESSION ANALYSIS AND CLASSIFICATION USING T₁-WEIGHTED MRI

By

Basma Hassan Ahmed Ali

A Thesis Submitted to the
Faculty of Engineering at Cairo University
in Partial Fulfillment of the
Requirements for the Degree of
MASTER OF SCIENCE
in
Biomedical Engineering and Systems

Under the Supervision of

Prof.Dr. Ayman Mohammed Eldeib

Assoc. Prof. Dr. Inas Ahmed Yassine

.....
Professor of Biomedical Engineering
Biomedical Engineering and systems
Faculty of Engineering, Cairo University

.....
Associate Professor
Biomedical Engineering and Systems
Faculty of Engineering, Cairo University

FACULTY OF ENGINEERING, CAIRO UNIVERSITY
GIZA, EGYPT
2019

ALZHEIMER'S DISEASE PROGRESSION ANALYSIS AND CLASSIFICATION USING T₁-WEIGHTED MRI

By

Basma Hassan Ahmed Ali

A Thesis Submitted to the
Faculty of Engineering at Cairo University
in Partial Fulfillment of the
Requirements for the Degree of
MASTER OF SCIENCE
in
Biomedical Engineering and systems

Approved by the
Examining Committee

Prof. Dr. Ayman Mohammed Eldeib (Thesis Main Advisor)
Professor, Biomedical Engineering and Systems, Cairo University

Assoc.Prof. Dr. Inas Ahmed Yassine (Advisor)
Associate Professor, Biomedical Engineering and Systems, Cairo University

Prof. Dr. Ahmed Hisham Kandil (Internal Examiner)
Professor, Biomedical Engineering and Systems, Cairo University

Prof. Dr. Samia Abd Alraziq Mashaly (External Examiner)
Professor in electronic research institute

FACULTY OF ENGINEERING, CAIRO UNIVERSITY
GIZA, EGYPT
2019

Engineer's Name: Basma Hassan Ahmed Ali
Date of Birth: 1/11/1990
Nationality: Egyptian
E-mail: bhassan@eng1.cu.edu.eg
Phone: 01006024076
Address: 115 waw, Hadayek El-Ahram, Giza
Registration Date: 1/10/2014
Awarding Date:/....../2019
Degree: Master of Science
Department: Biomedical Engineering and Systems



Supervisors:

Prof. Dr. Ayman Mohammed Eldeib
Assoc. Dr. Inas Ahmed Yassine

Examiners:

Prof. Dr. Samia Abd Alraziq Mashaly (External examiner)
-Professor in electronic research institute
Prof. Dr. Ahmed Hisham Kandil (Internal examiner)
Prof. Dr. Ayman Mohammed Eldeib (Thesis main advisor)
Assoc. Prof. Dr. Inas Ahmed Yassine (Advisor)

Title of Thesis:

Alzheimer's Disease Progression Analysis and Classification
for T₁-Weighted MRI

Key Words:

Alzheimer's disease; MRI; MMSE; SVM; VolBrain

Summary:

Alzheimer's disease (AD) is a considered one of the common elderly diseases. It is a type of dementia that causes changes in behavior in addition to memory loss because of the death of brain cells. There are three stages for Alzheimer disease named: Alzheimer's Disease patient (AD), Mild cognitive impairment (MCI) and Early stage. In this work, we proposed a promising method to classify the different categories of Alzheimer and the healthy control (HC) subjects using multiple T₁-weighted MRI scans of the whole brain volume directly to extract several features by subtracting the longitudinal data of different visits and compute the associated changes in the brain. These features are then fed to the Support Vector Machine (SVM) classifier. The main advantage of this method is that it doesn't involve lots preprocessing steps including the segmentation that was done to extract the hippocampus or amygdala or any other region of interest, which is considered as an expensive and complicated process. The second part of this thesis is employing a bio-statistical analysis to compute the cross-sectional correlation/regression between different clinical assessments such as MMSE,... and ... and four Volume of Interest (VOI) named hippocampus, amygdala, lateral ventricles and total brain volume formed of WM and GM. It was observed that MMSE is the most significant assessment, having a high correlation with the four VOI. The graphical representation of the volumetric changes in the different VOI was studied longitudinally along with the shrinkage rate of hippocampus, amygdala and overall brain volume as well as the enlargement rate of lateral ventricles through the progression stages of the disease compared to the normal subjects.

Disclaimer

I hereby declare that this thesis is my own original work and no part of it has been submitted for a degree qualification at any other university or institute.

I further declare that I have appropriately acknowledged all sources used and have cited them in the reference section.

Name: Basma Hassan Ahmed

Date:

Signature:

Acknowledgments

First and foremost, I thank **ALLAH**, the most gracious, the ever merciful for helping me finishing this work. I want to thank all those, who helped me by their knowledge and experience. I will always appreciate their efforts. I would like to offer my sincere thanks to **Dr. Mustafa El-Attar** for his cooperation and support and my supervisors **Prof. Dr. Ayman Eldeib** and **Assoc. Prof. Dr. Inas A. Yassine**. I owe them for valuable supervision, continuous encouragement, useful suggestions, and active help during this work. My sincere appreciation and gratitude to my family for their help and patience during the preparation of this work

Table of Contents

ACKNOWLEDGMENTS	I
LIST OF TABLES	IV
LIST OF FIGURES	V
NOMENCLATURE	VIII
ABSTRACT	X
CHAPTER 1 : INTRODUCTION	1
1.1. BRAIN ANATOMY	2
1.2. ALZHEIMER DISEASE.....	4
1.3. DIAGNOSIS OF ALZHEIMER DISEASE AND ITS PROGRESSION.....	5
1.3.1. STAGES OF ALZHEIMER’S PROGRESSION.....	5
1.3.1.1. MILD ALZHEIMER'S DISEASE: THE EARLY STAGE.....	6
1.3.1.2. MODERATE ALZHEIMER'S DISEASE: MIDDLE STAGE.....	6
1.3.1.3. SEVERE ALZHEIMER'S DISEASE: LATE STAGE.....	7
1.3.2. CLINICAL ASSESSMENTS	8
1.3.2.1. MINI MENTAL STATE EXAMINATION (MMSE).....	8
1.3.2.2. THE CLINICAL DEMENTIA RATING (CDR).....	8
1.3.2.3. FUNCTIONAL ACTIVITIES QUESTIONNAIRE (FAQ).....	9
1.3.2.4. GLOBAL DETERIORATION SCALE (GDSCALE).....	9
1.3.3. IMAGING TECHNIQUES.....	9
1.4. PROBLEM STATEMENT	10
1.5. THESIS STRUCTURES	11
 CHAPTER 2 : LITERATURE REVIEW AND RELATED WORK.....	 12
2.1. SEGMENT-BASED CLASSIFICATION OF ALZHEIMER’S DISEASE	12
2.1.1. VOXEL-BASED ANALYSIS	12
2.1.1.1. DIRECT APPROACH	13
2.1.1.2. STAND-SCORE APPROACH.....	14
2.1.1.3. COMPARE APPROACH.....	15
2.1.1.4. ATLAS APPROACH	15
2.1.2. VERTEX-BASED ANALYSIS.....	17
2.1.2.1. DIRECT APPROACH	17
2.1.2.2. ATLAS-BASED APPROACH	17
2.1.3. REGION OF INTEREST BASED ANALYSIS	19
2.2. STATISTICAL ANALYSIS	21
 CHAPTER 3 : CLASSIFICATION SYSTEM BASED ON THE WHOLE BRAIN	
VOLUME.....	27
3.1. INTRODUCTION	27

3.2. DATASET DESCRIPTION.....	27
3.3. BLOCK DIAGRAM OF THE PROPOSED SYSTEM.....	28
3.3.1. VOLUME ALIGNMENT	28
3.3.2. FEATURE EXTRACTION	29
3.3.3. FEATURE SELECTION	30
3.3.3.1. TWO SAMPLE T-TEST	31
3.3.3.2. FISHER SCORE.....	31
3.3.4. CLASSIFICATION TECHNIQUE	32
CHAPTER 4 : BIO-STATISTICAL ANALYSIS	35
4.1. INTRODUCTION	35
4.2. DATASET DESCRIPTION.....	35
4.3. ROI VOLUME CALCULATION.....	35
4.3.1. VOLBRAIN	36
4.4. CORRELATION BETWEEN THE CLINICAL ASSESSMENTS AND VOLUMES OF INTEREST.	38
4.5. LONGITUDINAL STUDY OF THE VOLUMETRIC BRAIN CHANGE THROUGH ALZHEIMER STAGES	39
CHAPTER 5 : RESULTS AND DISCUSSION.....	41
5.1. INTRODUCTION.....	41
5.2. CLASSIFICATION PERFORMANCE BASED ON THE WHOLE BRAIN VOLUME.....	41
5.3. STATA ANALYSIS RESULTS	42
5.3.1. CORRELATION BETWEEN THE CLINICAL ASSESSMENTS AND VOLUMES OF INTEREST	42
5.3.2. LONGITUDINAL STUDY OF THE VOLUMETRIC BRAIN CHANGE THROUGH ALZHEIMER STAGES	48
CHAPTER 6 : CONCLUSION AND FUTURE WORK.....	55
6.1. CONCLUSION	55
6.2. FUTURE WORK.....	56
REFERENCES	57

List of Tables

Table 2.1 Summarization of some related works and percentage accuracies reported in each study to classify AD from HC or MCI.....	20
Table 2.2 Absolute brain region volume (mm ³) (mean $\pm$ standard deviation) values of each group whose brain regions showed linear volume reduction towards AD progression	Error! Bookmark not defined.
Table 2.3 Multiple linear regression coefficients between brain region volumes and explanatory variables.....	23
Table 4.1 Cross-sectional analysis according to the clinical status.....	35
Table 4.2 Absolute brain region volume (mean $\pm$ standard deviation) values of each category whose brain regions showed linear volume reduction towards AD progression	39
Table 5.1 Accuracies of SVM classifier.....	42
Table 5.2 Correlation coefficient R_s with the four clinical assessments, sex and age....	43
Table 5.3 Multiple linear regression coefficients between brain region volumes and explanatory variables.....	44

List of Figures

Figure 1.1 Main four brain lobes [4]	2
Figure 1.2 Limbic system [5]	3
Figure 1.3 Hippocampus shape [7].....	3
Figure 1.4 Healthy and damaged brain cells [10].....	4
.....	5
Figure 1.5 An illustration comparing a normal brain and a brain affected by Alzheimer's disease [11].....	5
Figure 1.6 Early stage of Alzheimer [1]	6
Figure 1.7 Moderate stage of Alzheimer [1]	7
Figure 1.8 Severe Stage of Alzheimer [1]	7
Figure 1.9 Healthy and advanced Alzheimer brain [14]	8
Figure 2.1 Histogram of probability Map of Tissue.....	12
Figure 2.2 Preprocessing pipeline of statistical Parametric Mapping (SPM) [28].....	13
Figure 2.3 Grey matter, white matter and CSF Tissue masks [27].	14
.....	16
Figure 2.4 Bootstrap Method [31]	16
Figure 2.5 Cortical Thickness Calculation [32]	17
Figure 2.6 Cortex gyrus [34]	18
Figure 2.7 Hippocampus and Amygdala position [43]	19
.....	23
Figure 2.9 Linear correlation between normalized volume and MMSE of each individual subject. Regression coefficients are inserted in the equation of each plot [52].	23
.....	23
Figure 2.10 Two-year changes in clinical and cognitive measures differed significantly between the atrophy subtypes (limbic predominant [LPMRI], typical AD [tAD MRI], and hippocampal sparing [HpSpMRI]). Participants with HpSp decline more quickly than those with the other subtypes, including a significantly greater rate of increasing (a) clinical dementia severity (CDR, $p=0.013$) and (b) faster cognitive decline on the MMSE ($p=0.002$), as well as (c) functional impairment (FAQ, $p=0.020$) [53].	24
Figure 2.11 Adjusted total hippocampal volume measurements of mutation carriers (relative to time of clinical diagnosis of AD) and controls (relative to the date of their last scan [54])......	25
.....	26
Figure 2.12 Adjusted whole-brain volume measurements of mutation carriers (relative to time of clinical diagnosis of AD) and controls (relative to the date of their last scan [54].	26
.....	26
Figure 3.1 Block Diagram of overall proposed system.	28
Figure 3.2 Coronal magnetic resonance imaging (MRI) scans of an 82-year-old healthy control woman and their subtraction image. (a): Baseline MRI, (b): repeated scan after one year, (c): another repeated scan after two years from the baseline, (d): subtraction image after aligning the repeated scans onto the baseline.	29
.....	29
Figure 3.3 Coronal magnetic resonance imaging (MRI) scans of an 82-year-old man with familial Alzheimer's disease and their subtraction image. (a): Baseline MRI, (b): repeated scan after 6-month, (c): another repeated scan after one years from the baseline, (d): subtraction image after aligning the repeated scans onto the baseline.	30

Figure 3.4 Coronal magnetic resonance imaging (MRI) scans of an 82-year-old MCI man and their subtraction image. (a): Baseline MRI, (b): repeated scan after one year, (c): another repeated scan after two years from the baseline, (d): subtraction image after aligning the repeated scans onto the baseline.	30
Figure 3.5 Support vectors [68]	33
Figure 3.6 Kernel function for non-linear Classification [68]	33
Figure 3.7 K-fold cross validation [70]	34
Figure 3.8 Leave one out Cross Validation [70]	34
Figure 4.1 Flow chart of volume estimation in Volbrain	36
Figure 4.2 VolBrain steps [72]	37
Figure 4.3 VolBrain subcortical structure (a) Healthy control subject, (b): AD patient, (c) MCI patient.	38
Figure 4.4 Ranges of correlation coefficient (R_s) [73].	39
Figure 4.5 Normalized brain volumes (mean $\pm$ standard deviation) expressed as a percentage of the total intracranial volume (TIV) for each group of healthy control subjects, MCI patients and AD patients.	40
Figure 5.1 Single Linear regression between normalized volume of hippocampus and MMSE of each individual subject.	45
Figure 5.2 Single Linear regression between normalized volume of hippocampus and CDR of each individual subject.	46
Figure 5.3 Single Linear regression between normalized volume of amygdala and MMSE of each individual subject.	47
Figure 5.4 Single Linear regression between normalized volume of lateral ventricles and MMSE of each individual subject.	47
Figure 5.5 Single Linear regression between normalized volume of brain (GM and WM) and MMSE of each individual subject.	47
Figure 5.6 Normalized hippocampus volume measurements of healthy control (HC) subjects starting from the baseline visit and along the follow-up visits.	48
Figure 5.7 Normalized hippocampus volume measurements of MCI patients starting from the baseline visit and along the follow-up visits.	49
Figure 5.8 Normalized hippocampus volume measurements of AD patients starting from the baseline visit and along the follow-up visits.	49
Figure 5.9 Normalized Amygdala volume measurements of HC subjects starting from the baseline visit and along the follow-up visits.	50
Figure 5.10 Normalized Amygdala volume measurements of MCI patients starting from the baseline visit and along the follow-up visits.	50
Figure 5.11 Normalized Amygdala volume measurements of AD patients starting from the baseline visit and along the follow-up visits.	51
Figure 5.12 Normalized Lat. Ventricle volume measurements of HC subjects starting from the baseline visit and along the follow-up visits.	51
Figure 5.13 Normalized Lat. Ventricle volume measurements of MCI patients starting from the baseline visit and along the follow-up visits.	52
Figure 5.14 Normalized Lat. Ventricle volume measurements of AD patients starting from the baseline visit and along the follow-up visits.	52
Figure 5.15 Normalized Brain (GM and WM) volume measurements of HC patients starting from the baseline visit and along the follow-up visits.	53
	53

Figure 5.16 Normalized Brain (GM and WM) volume measurements of MCI patients starting from the baseline visit and along the follow-up visits.....	53
Figure 5.17 Normalized Brain (GM and WM) volume measurements of AD patients starting from the baseline visit and along the follow-up visits.....	54

Nomenclature

AAL	Automated Anatomical Labeling
AD	Alzheimer's disease
ADNI	Alzheimer's disease Neuroimaging Initiative
ANOVA	Analysis of Variance
BET	Brain Extraction Tool
BOVW	Bag-of-Visual-Words
CDR	Clinical Dementia Rating
CHF	Circular harmonic functions
CT	Computed Tomography
CSF	Cerebrospinal Fluid
DL-CNN	Deep Learning- Convolutional Neural Networks
EM	Expectation and maximization
EEG	Electroencephalography
FAQ	Functional Activities Questionnaire
FMRI	Functional Magnetic Resonance Imaging
FSL	FMRIB Software Library
GDSCALE	Global Deterioration Scale
GM	Gray Matter
GUI	Graphical user interface
HC	Healthy Control
IADL	Instrumental activities of daily living
ITK	Insight Segmentation and Registration Toolkit
KNN	K-nearest neighbor classifier
LDA	Linear discriminant analysis
LOOCV	Leave One Out Cross Validation
MCI	Mild cognitive impairment
MLE	Maximum likelihood estimate
MMSE	Mini Mental State Examination
MRI	Magnetic Resonance Imaging
NIA	National Institute on Aging
NIBIB	National Institute of Biomedical Imaging and Bioengineering
NTI	Normalized Thickness Index
OPLS	Orthogonal Partial Least Squares to Latent Structures.
PCA	Principle component analysis
PCC	Posterior cingulate cortex
PET	Positron emission tomography
RBF	Radial Basis Function
ROC	Receiver Operating Curve
ROI	Region of interest
TIV	Total Intracranial Volume
SIFT	Scale-invariant feature transform
SPECT	Single-photon emission computed tomography
SPHARM	Spherical harmonics
SPHARM-PDM	Spherical Harmonics-Point Distribution Model

SPM	Statistical Parametric Mapping
SURF	Speeded-Up Robust Features
SVM	Support vector machine
SVM-RFE	SVM Recursive Feature Elimination
VBM	Voxel-based Morphometric
VOI	Volume of interest
VolBrain	Volume of Brain
WM	White Matter

Abstract

Alzheimer's disease (AD) is a considered one of the common elderly diseases. It is a type of dementia that causes changes in the patient behavior in addition to memory loss because of the death of brain cells. It is considered a chronic neurodegenerative progressive disease which gets worse over time. In the Early stage, the patient may perform his/her usual activities as he/she still drive, work and deal with other people but with less efficiency. Later occurs the Mild Cognitive Impairment (MCI) stage, known as moderate Alzheimer's disease, that is considered the longest stage and may last for many years in which the patient may suffer from many troubles like confusing words, getting frustrated or angry, or acting in unexpected ways. AD, is the severe stage or late stage, where the patients lose their ability of responding to their usual environment and that ends with the patient death.

The Hippocampus and Amygdala regions, subregions of the limbic system, are very good indicators for the presence of AD and considered as the most affected part in terms of shape and volume by the Alzheimer deterioration since they are responsible for the memory storage. Moreover, In Alzheimer's disease, there is an overall shrinkage of brain tissues in addition to enlargement of the lateral ventricles.

There is no single medical test that proves a person has Alzheimer's. Diagnosing Alzheimer's involves a complete assessment that is formed of few tests such as : Mini Mental State Examination (MMSE) and Clinical Dementia Rating Scale (CDR), as the standard dementia screening and staging severity tests. There are also other clinical assessments that are used such as The Functional Activities Questionnaire (FAQ) and The Global Deterioration Scale (GDScale). These four assessments are based on a scoring system.

In this work, we propose a promising method to classify the different categories of Alzheimer and the healthy control (HC) subjects using a series of longitudinal T₁-weighted MRI scans of the whole brain volume for every follow-up visit. The difference volume of each visit is computed by subtracting each follow-up scan from the baseline MRI to get the 3D feature vector associated with every subject. These features are then fed to the decision support system. The main advantage of the proposed system is eliminating most of the preprocessing steps, which in its turn decreases the processing time and though the overall cost in terms of time and cost. The preprocessing module is formed of the alignment of the longitudinal dataset to the Atlas as well as the down sampling of the volume in order to decrease the processing time.

Both of Two sample T-Test and Fisher Score are studied for dimensionality reduction purposes to overcome the overfitting problem followed by SVM classifier for the classification between HC and MCI subjects, HC and AD subjects and MCI and AD patients. Leave one out cross validation (LOOCV) and 10-Fold are used to study the system robustness based on the accuracy.

The second part of this thesis is employing a bio-statistical analysis to compute the cross-sectional correlation and regression model between different clinical assessments such as MMSE,... and ... and four Volume Of Interest (VOI) named hippocampus,